We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Reports Increased Use of Competitive Generic Therapy Program
FDA Reports Increased Use of Competitive Generic Therapy Program
The FDA is reviewing significantly higher numbers of generic drugs under its Competitive Generic Therapy (CGT) pathway, the latest quarterly report on the agency’s GDUFA II performance reveals.